Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1723-1730

  Yang, Xiaojun ^a   Cai, Hui ^a   Liang, Yuhe ^b   Chen, Lin ^c   Wang, Xiangdong ^b   Si, Ruohuang ^a   Qu, Kunpeng ^a   Jiang, Zebin ^a   Ma, Bingqiang ^a   Miao, Changfeng ^a   Li, Jing ^a   Wang, Bin ^a   Gao, Peng ^a  

^a GANSU PROVINCIAL HOSPITAL   (China)

^b Dept of Neurology Baoji City People's Hospital   (China)

^c LANZHOU UNIVERSITY   (China)

Author keywords

C Myc; Gastric cancer; Let 7b; Mutidrug resistance

Indexed keywords

CISPLATIN; FLUOROURACIL; MICRORNA; MICRORNA LET7B; MYC PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; 3' UNTRANSLATED REGION; MESSENGER RNA; MIRNLET7 MICRORNA, HUMAN; MYC PROTEIN, HUMAN; RNA; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ANALYSIS OF VARIANCE; ARTICLE; AUTOREGULATION; BINDING SITE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE CLUSTER; HUMAN; HUMAN CELL; IC50; MTT ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STOMACH CANCER; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL DIFFERENTIATION; COMPARATIVE STUDY; DRUG RESISTANCE; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MULTIDRUG RESISTANCE; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEEDBACK, PHYSIOLOGICAL; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; INHIBITORY CONCENTRATION 50; MICRORNAS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM; STOMACH NEOPLASMS; TRANSFECTION; VINCRISTINE;

EID: 84924907597     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3757     Document Type: Article

References (50)

1. Lee JH, Kim KM, Cheong JH and Noh SH: Current management and future strategies of gastric cancer. Yonsei Med J 53: 248-257, 2012.
2. Hudler P: Genetic aspects of gastric cancer instability. Sci World J: 2012: 761909, 2012.
3. Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J and Forman D (EUROCARE Working Group): Explaining gastric cancer survival differences among European countries. Int J Cancer 109: 737-741, 2004.
4. Bonenkamp JJ, Hermans J, Sasako M, et al: Extended lymphnode dissection for gastric cancer. N Engl J Med 340: 908-914, 1999.
5. Kaneko S and Yoshimura T: Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 84: 400-405, 2001.
6. Fan D and Liu X: New progresses in researches on multidrug resistance in gastric cancer. Chin J Digest 20: 77-78, 2000.
7. Milne AN, Sitarz R, Carvalho R, Carneiro F and Offerhaus GJ: Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Curr Mol Med 7: 15-28, 2007.
8. Eilers M and Eisenman RN: Myc's broad reach. Genes Dev 22: 2755-2766, 2008.
9. Herkert B and Eilers M: Transcriptional repression: the dark side of myc. Genes Cancer 1: 580-586, 2010.
10. Miller MD, Thomas SD, Islam A, Muench D and Sedoris K: C-Myc and cancer metabolism. Clin Cancer Res 18: 5546-5553, 2012.
11. Walker TL, White JD, Esdale WJ, Burton MA and DeCruz EE: Tumour cells surviving in vivo cisplatin chemotherapy display elevated cmyc expression. Br J Cancer 73: 610-614, 1996.
12. Marazzi L, Parodi MT, Martino DD, Ferrari S and Tonini GP: Coordinate change of c-myc, transferrin receptor and H3 gene expression precedes induction of haemoglobin-producing cells of the leukaemia K562 cell line treated with cisdiamminedichloroplatinum II. Anticancer Res 11: 947-952, 1991.
13. Kashani-Sabet M, Lu Y, Leong L, Haedicke K and Scanlon KJ: Differential oncogene amplification in tumour cells from a patient treated with cisplatin and 5-FU. Eur J Cancer 26: 383-390, 1990.
14. Vandenboom TG II, Li Y, Philip PA and Sarkar FH: MicroRNA and cancer: tiny molecules with major implications. Curr Genomics 9: 97-109, 2008.
15. Iorio MV and Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
16. Peter ME: Regulating cancer stem cells the miR way. Cell Stem Cell 6: 4-6, 2010.
17. Adam L, Zhong M, Choi W, et al: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15: 5060-5072, 2009.
18. Bourguignon LY, Spevak CC, Wong G, Xia W and Gilad E: Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284: 26533-26546, 2009.
19. Blower PE, Chung JH, Verducci JS, et al: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7: 1-9, 2008.
20. Roush S and Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 18: 505-516, 2008.
21. Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-1030, 2007.
22. Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-677, 2007.
23. Yang N, Kaur S, Volinia S, et al: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68: 10307-10314, 2008.
24. Kim CH, Kim HK, Rettig RL, et al: miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 4: 79, 2001.
25. Broxterman HJ, Gotink KJ and Verheul HM: Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12: 114-126, 2009.
26. Fojo T: Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 10: 59-67, 2007.
27. Gatti L and Zunino F: Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 111: 127-148, 2005.
28. Fan D, Zhang X, Chen X, et al: Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 20: 360-365, 2005.
29. Chuman Y, Sumizawa T, Takebayashi Y, et al: Expression of the multidrug resistance associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 66: 274-279, 1996.
30. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y and Saji S: The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: Time-and p53 expression-dependency of anti-cancer drugs. Oncol Rep 14: 609-615, 2005.
31. Ning H, Li T, Zhao L, et al: TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol Ther 5: 950-956, 2006.
32. Chang L, Guo F, Wang Y, et al: MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. Pathol Oncol Res 20: 93-98, 2014.
33. Yan LH, Wang XT, Yang J, et al: Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation. World J Gastroenterol 19: 4155-4165, 2013.
34. Eitan R, Kushnir M, Lithwick-Yanai G, et al: Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 114: 253-259, 2009.
35. Chen Y, Zuo J, Liu Y, Gao H and Liu W: Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer 29: 1006-1011, 2010.
36. Schultz J, Lorenz P, Gross G, Ibrahim S and Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18: 549-557, 2008.
37. Sampson VB, Rong NH, Han J, et al: MicroRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67: 9762-9770, 2007.
38. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
39. RybakA, Fuchs H, Smirnova L, et al: A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 10: 987-993, 2008.
40. Yang XJ, Lin XJ, Zhong XM, et al: Double negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 70: 9463-9472, 2010.
41. Chang TC, Zeitels LR, Hwang HW, et al: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci USA 106: 3384-3389, 2009.
42. Cotterman R and Knoepfler PS: N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b. PLoS One 4: e5799, 2009.
43. Molenaar JJ , Domingo-Fernández R, Ebus ME, et al: LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44: 1199-1206, 2012.
44. Laurenti E, Varnum-Finney B, Wilson A, et al: Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 3: 611-624, 2008.
45. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA and Parada LF: Loss of Nmyc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Gene Dev 6: 2235-2247, 1992.
46. Konopleva M, Tabe Y, Zeng Z and Andreeff M: Therapeutic targeting of micro environmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 12: 103-113, 2009.
47. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
48. Wang Z, Li Y, Banerjee S and Sarkar FH: Emerging role of Notch in stem cells and cancer. Cancer Lett 279: 8-12, 2009.
49. Wang ZW, Li YW, Ahmad A, et al: Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118, 2010.
50. Ahmed N, Abubaker K, Findlay J and Quinn M: Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 114: 21-34, 2013.